ArticlePloS one2021
To achieve 95-95-95 targets we must reach men and youth: High level of knowledge of HIV status, ART coverage, and viral suppression in the Botswana Combination Prevention Project through universal test and treat approach.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01965470 (Botswana Combination Prevention Project), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Achieving the UNAIDS 90-90-90 targets: a comparative analysis of four large community randomised trials delivering universal testing and treatment to reduce HIV transmission in sub-Saharan Africa.BMC public health · 2022Pooled it
- Peer network approaches for improving HIV testing, prevention and care utilisation among men in sub-Saharan Africa: a scoping review.BMJ open · 2026Article
- Decomposing gender gaps in HIV service outcomes.BMJ global health · 2026Article
- Article
- The impact of migrant-inclusive policy on Botswana's universal HIV treatment program: a retrospective analysis of the national HIV treatment program data (2016-2022).Frontiers in public health · 2026Observational
- Biological and Social Predictors of HIV-1 RNA Viral Suppression in ART Treated PWLH in Sub-Saharan Africa.Tropical medicine and infectious disease · 2025Article
- Article
- Achieving the fast track 90-90-90 and 95-95-95 targets in sub-Saharan Africa: A rapid review.Journal of public health in Africa · 2025Review
- Viral load dynamics among adults receiving HIV care in rural North-Eastern South Africa, 2015-2020: insights from a population-based record linkage study.Frontiers in public health · 2025Article
- Progress towards the UNAIDS 95-95-95 targets in the Fifth Botswana AIDS Impact Survey (BAIS V 2021): a nationally representative survey.The lancet. HIV · 2024Article
- Self-reported sexually transmitted infections among men and women in Papua New Guinea: A cross-sectional study.Health science reports · 2024Article
- Opportunistic Infections among newly diagnosed HIV patients in the largest tertiary facility in Ghana.Annals of global health · 2024Article
- Assessment of an instrument scale measuring the knowledge of antiretroviral therapy among people living with HIV.BMC public health · 2023Article
- Article
- Utility of a machine-guided tool for assessing risk behaviour associated with contracting HIV in three sites in South Africa.Informatics in medicine unlocked · 2023Article
- Epidemiological and viral characteristics of undiagnosed HIV infections in Botswana.BMC infectious diseases · 2022Article
- Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana.AIDS research and therapy · 2022Review
- The role of machine learning in HIV risk prediction.Frontiers in reproductive health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundIncreasing HIV treatment coverage is crucial to reducing population-level HIV incidence.
methodsThe Botswana Combination Prevention Project (BCPP) was a community randomized trial examining the impact of multiple prevention interventions on population-level HIV incidence and was conducted from October 2013 through June 2017. Home and mobile campaigns offered HIV testing to all individuals ≥ age 16. All identified HIV-positive persons who were not on antiretroviral therapy (ART) were referred to treatment and tracked to determine linkage to care, ART status, retention in treatment, and viral suppression.
resultsOf an estimated total of 14,270 people living with HIV (PLHIV) residing in the 15 intervention communities, BCPP identified 13,328 HIV-positive persons (93%). At study start, 10,703 (80%) of estimated PLHIV knew their status; 2,625 (20%) learned their status during BCPP, a 25% increase with the greatest increases occurring among men (37%) and youth (77%). At study start, 9,258 (65%) of estimated PLHIV were on ART. An additional 3,001 persons started ART through the study. By study end, 12,259 had initiated and were retained on ART, increasing coverage to 93%. A greater increase in ART coverage was achieved among men (40%) compared to women (29%). Of the 11,954 persons who had viral load (VL) test results, 11,687 (98%) were virally suppressed (HIV-1 RNA ≤400 copies/mL). Overall, 82% had documented VL suppression by study end.
conclusionsKnowledge of HIV-positive status and ART coverage increased towards 95-95 targets with universal testing, linkage interventions, and ART. The increases in HIV testing and ART use among men and youth were essential to reaching these targets. CLINICAL TRIAL NUMBER: NCT01965470.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.